Ocular Therapeutix Inc (NASDAQ:OCUL) currently has a daily average trading volume of 908.43K but it saw 1033926 shares traded in last market. With a market cap of 1.20B USD, the company’s current market price of $7.64 came falling about -6.03 while comparing to the previous closing price of $8.13. In past 52 weeks, the stock remained buoying in the range of price level as high as $11.77 and as low as $4.06. In the recent trading on the day, stock has struck highest price mark of $7.63 while lowest mark touched by it was $8.2.
Taking a look at 20-day trading activity of Ocular Therapeutix Inc (OCUL) gives us an average price of $7.98, while its current price level is -35.12% below from 52-week high level whereas it is 88.18% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $8.60 while that of 200 days or SMA-200 reads an average of $8.09. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.18% during that period while stretching the period over a month that decreases to 4.96%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 39.11 which implies that the stock is in neutral territory.
TD Cowen upgraded its recommendation for the stock as a “Buy” from “Hold” on June 20, 2024 while assigning a price target range of $7-$11. Piper Sandler issued its recommendations for the stock as it resumed the price target for the stock is $15.
Over the week, OCUL’s stock price is moving -1.80% down while it is -13.96% when we observe its performance for the past one month. Year-to-date it is -10.54% down and over the past year, the stock is showing an upside performance of 54.34%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of -0.22 while estimate for next year EPS is -1.07. In next quarter, company is expected to be making quarterly sales of $16.79M as analysts are expecting the sales for current fiscal year at $63.77M and seeing the company making $72.46M in sales next year. Moreover, analysts are in estimates of $16.89M for current-quarter revenue.
Currently, Ocular Therapeutix Inc’s total number of outstanding shares is 156.65M with 1.06% of that held by the insiders while 91.08% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -40.98% and return on equity (ROE) at -96.89%. Stock’s beta reads 1.32. Stock has a price to book (P/B) ratio of 3.40 while price to sale or P/S ratio amounts to 19.55. Its return on asset (ROA) is -53.42% on average.
